Welcome to our dedicated page for Galapagos Nv news (Ticker: GLPG), a resource for investors and traders seeking the latest updates and insights on Galapagos Nv stock.
Galapagos NV (GLPG) is a clinical-stage biotechnology leader advancing innovative small molecule medicines and cell therapies for complex diseases. This dedicated news hub provides investors and industry professionals with essential updates on the company's research milestones, strategic collaborations, and regulatory developments.
Access authoritative coverage of GLPG's progress in oncology, immunology, and inflammatory disease research. Our curated news collection includes:
• Clinical trial updates for novel therapeutic candidates
• Strategic partnership announcements with biopharma innovators
• Financial reporting and corporate development news
• Technology advancements in decentralized cell therapy production
Bookmark this page for real-time tracking of GLPG's pioneering work in precision medicine and its expanding pipeline addressing high unmet medical needs.
Excellos Inc., a cell therapy CDMO member of Blood Centers of America (BCA), has been selected to manufacture Galapagos' CAR-T cell therapy candidate, GLPG5101, for its FDA-cleared ATALANTA-1 clinical study in patients with relapsed/refractory non-Hodgkin lymphoma in the U.S. Excellos will provide end-to-end manufacturing at its new facility in San Diego, CA, using Galapagos' innovative, decentralized manufacturing platform.
This platform aims to address limitations in CAR-T cell therapy production, offering greater speed and scalability with a median vein-to-vein time of seven days. The collaboration is part of a strategic agreement between Galapagos' U.S. entity and BCA, which will provide decentralized manufacturing services for Galapagos' CAR-T cell therapy candidates across the U.S., close to cancer treatment centers.
BridGene Biosciences has expanded its strategic collaboration with Galapagos NV (NASDAQ: GLPG) to develop a selective oral SMARCA2 PROTAC for precision oncology. The collaboration, which builds on their January 2024 partnership, combines BridGene's PROTAC discovery engine with Galapagos' expertise in selective ATPase small molecules. BridGene is eligible to receive up to $159 million in total payments, including upfront and milestone payments, as well as tiered royalties on net sales. Galapagos will have exclusive rights for further development and commercialization of the preclinical candidate.
This expanded partnership aims to advance drug discovery for challenging oncology targets, leveraging the strengths of both companies to develop precision medicines for cancer patients with critical unmet needs. The collaboration underscores the importance of strategic alliances in advancing drug development efforts and validates BridGene's innovative approach in small molecule drug discovery for hard-to-drug targets.
Adaptimmune and Galapagos have entered a clinical collaboration to evaluate Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer. The trial aims to leverage Galapagos' decentralized manufacturing platform to improve efficacy and durability. Initial trials showed an 80% response rate with partial responses in four out of five patients. Adaptimmune will receive $70M upfront, $30M in R&D funding, and potentially up to $465M in milestone payments, with additional tiered royalties. Galapagos has an option to license uza-cel for global development and commercialization.
Scipher Medicine announced that Galapagos (GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD), following preclinical validation work. This collaboration will trigger a milestone payment to Scipher and allow them to receive additional payments based on future regulatory and sales milestones. The partnership is aimed at developing therapies for unmet needs in IBD using Scipher's Spectra™ platform, which leverages extensive molecular data to enhance drug response rates.
Galapagos NV and Gilead Sciences have announced the halt of the ISABELA Phase 3 clinical studies for ziritaxestat, an investigational autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF). This decision follows the Independent Data Monitoring Committee's review, which indicated that the benefit-risk profile of ziritaxestat no longer supports ongoing trials. The ISABELA program aimed to enroll 1,500 patients, but all trials, including a Phase 2a extension, will be discontinued. Both companies expressed disappointment but remain committed to advancing IPF research.
Galapagos NV (GLPG) announces the completion of Selvita S.A.'s acquisition of Fidelta for €31.2M. This strategic move nearly doubles Selvita's revenues, enhancing its drug discovery services. Fidelta, located in Croatia, employs 181 scientists and has a strong history in inflammation and fibrosis research. The acquisition strengthens Selvita’s position in the European contract research market and allows Fidelta to continue providing services to Galapagos for five years, ensuring ongoing collaboration.
On November 23, 2020, Galapagos NV (GLPG) announced the acquisition of Fidelta d.o.o. by Selvita S.A. for an enterprise value of €31.2M, to be paid in cash. This acquisition is poised to enhance Selvita's position as a leading preclinical contract research organization in Europe, almost doubling its revenues. Fidelta, currently providing drug discovery services, will continue its operations for Galapagos for the next five years. The deal is expected to close on January 4, 2021, and will significantly expand Selvita's integrated drug discovery services.
